CoChat

Retinal Ganglion Cell Survival and Axon Regeneration after Optic Nerve Injury: Role of Inflammation and Other Factors

Open access
Wong, Kimberly A., Benowitz, Larry I. · 2022 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.

Abstract

The optic nerve, like most pathways in the mature central nervous system, cannot regenerate if injured, and within days, retinal ganglion cells (RGCs), the neurons that extend axons through the optic nerve, begin to die. Thus, there are few clinical options to improve vision after traumatic or ischemic optic nerve injury or in neurodegenerative diseases such as glaucoma, dominant optic neuropathy, or optic pathway gliomas. Research over the past two decades has identified several strategies to enable RGCs to regenerate axons the entire length of the optic nerve, in some cases leading to modest reinnervation of di- and mesencephalic visual relay centers. This review primarily focuses on the role of the innate immune system in improving RGC survival and axon regeneration, and its synergy with manipulations of signal transduction pathways, transcription factors, and cell-extrinsic suppressors of axon growth. Research in this field provides hope that clinically effective strategies to improve vision in patients with currently untreatable losses could become a reality in 5–10 years.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms231710179

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Inflammation-induced optic nerve regeneration and the role of Oncomodulin (Ocm). (a) Negative control: Absence of axon regeneration following optic nerve injury (asterisk: site of optic nerve crush injury). (b) Intraocular inflammation induced by injury to the lens (shown here) or by other means cited in the text enables retinal ganglion cells (RGCs) to regenerate axons past the injury site. (c) Intraocular inflammation is associated with a rapid infiltration of Gr-1-positive neutrophils (red) that express high levels of Ocm (green). (d) P1, a peptide antagonist of Ocm based on the N-terminus of the protein, suppresses Zymosan-induced regeneration. (e) Slow-release polymer beads containing the cAMP analog CPT-cAMP induce minimal regeneration after optic nerve injury. (f) Extensive regeneration with slow-release beads containing Ocm + CPT-cAMP [5,6,13].
Figure 1 Inflammation-induced optic nerve regeneration and the role of Oncomodulin (Ocm). (a) Negative control: Absence of axon regeneration following optic nerve injury (asterisk: site of optic nerve crush injury). (b) Intraocular inflammation induced by injury to the lens (shown here) or by other means cited in the text enables retinal ganglion cells (RGCs) to regenerate axons past the injury site. (c) Intraocular inflammation is associated with a rapid infiltration of Gr-1-positive neutrophils (red) that express high levels of Ocm (green). (d) P1, a peptide antagonist of Ocm based on the N-terminus of the protein, suppresses Zymosan-induced regeneration. (e) Slow-release polymer beads containing the cAMP analog CPT-cAMP induce minimal regeneration after optic nerve injury. (f) Extensive regeneration with slow-release beads containing Ocm + CPT-cAMP [5,6,13].CC BY · PubMed Central
Figure 2 Macrophage-derived SDF1 complements the effects of Ocm (previous page). (a) SDF1 (red) is highly expressed in F4/80 macrophages that infiltrate the vitreous by 24 h after intraocular injection of Zymosan. (b) Among multiple trophic factors tested in dissociated adult retinal cell cultures, SDF1 is the only factor that enhances the effects of Ocm (combined with co-factors mannose and CPT-cAMP). B: Brain-derived neurotrophic factor (BDNF); C: ciliary neurotrophic factor (CNTF); G: glial cell-derived trophic factor (GDNF); L: leukemia inhibitory factor (LIF); T: tumor-necrosis factor (TNF); F: fibroblast growth factor-2; I: insulin-like growth factor 2 (IGF2). *** p < 0.001. (c) SDF1 combined with Ocm and CPT-cAMP induces similar levels of regeneration as Zymosan. (d) SDF1 alters the response of different RGC populations to PTEN deletion. aRGCs, the population that extends axons in response to Pten deletion, are identified by virtue of expressing GFP from the Kcng4 promoter. Axons arising from all RGCs, whether aRGCs or non-aRGCs, are labeled with CTB. Top row: In response to SDF1 alone, regenerating GFP-negative axons all arise from non-aRGCs. Middle row: Pten deletion alone induces regeneration primarily from aRGCs (note extensive overlap of GFP and CTB in last panel). Bottom row: Combining SDF1 and Pten deletion suppresses regeneration from aRGCs while strongly increasing overall levels of regeneration from non-αRGCs. (e) Schematic illustration showing the response of different RGC populations to various treatments. Top row: AAV2 expressing anti-Pten shRNA (AAV2-shPten) induces axon growth primarily from aRGCs (green cells). AAV2-shLuciferase virus (AAV2-shLuc) has no effects. Middle row: Either recombinant SDF1 (rSDF1) or AAV2 expressing SDF1 (AAV2-SDF1) induces moderate axon growth primarily from non-aRGCs (middle left: orange cells). When combined with Pten deletion, SDF1 induces non-aRGCs to regenerate lengthy axons but prevents aRGCs from responding to Pten deletion (middle right). Bottom row: Zymosan elevates levels of neutrophil-derived Ocm, macrophage-derived SDF1, and other factors, stimulating regeneration from both α- and non-αRGCs (bottom left); Pten deletion combined with Zymosan strongly augments outgrowth from both subtypes (bottom right) [8]. Asterisks show lesion site.
Figure 2 Macrophage-derived SDF1 complements the effects of Ocm (previous page). (a) SDF1 (red) is highly expressed in F4/80 macrophages that infiltrate the vitreous by 24 h after intraocular injection of Zymosan. (b) Among multiple trophic factors tested in dissociated adult retinal cell cultures, SDF1 is the only factor that enhances the effects of Ocm (combined with co-factors mannose and CPT-cAMP). B: Brain-derived neurotrophic factor (BDNF); C: ciliary neurotrophic factor (CNTF); G: glial cell-derived trophic factor (GDNF); L: leukemia inhibitory factor (LIF); T: tumor-necrosis factor (TNF); F: fibroblast growth factor-2; I: insulin-like growth factor 2 (IGF2). *** p < 0.001. (c) SDF1 combined with Ocm and CPT-cAMP induces similar levels of regeneration as Zymosan. (d) SDF1 alters the response of different RGC populations to PTEN deletion. aRGCs, the population that extends axons in response to Pten deletion, are identified by virtue of expressing GFP from the Kcng4 promoter. Axons arising from all RGCs, whether aRGCs or non-aRGCs, are labeled with CTB. Top row: In response to SDF1 alone, regenerating GFP-negative axons all arise from non-aRGCs. Middle row: Pten deletion alone induces regeneration primarily from aRGCs (note extensive overlap of GFP and CTB in last panel). Bottom row: Combining SDF1 and Pten deletion suppresses regeneration from aRGCs while strongly increasing overall levels of regeneration from non-αRGCs. (e) Schematic illustration showing the response of different RGC populations to various treatments. Top row: AAV2 expressing anti-Pten shRNA (AAV2-shPten) induces axon growth primarily from aRGCs (green cells). AAV2-shLuciferase virus (AAV2-shLuc) has no effects. Middle row: Either recombinant SDF1 (rSDF1) or AAV2 expressing SDF1 (AAV2-SDF1) induces moderate axon growth primarily from non-aRGCs (middle left: orange cells). When combined with Pten deletion, SDF1 induces non-aRGCs to regenerate lengthy axons but prevents aRGCs from responding to Pten deletion (middle right). Bottom row: Zymosan elevates levels of neutrophil-derived Ocm, macrophage-derived SDF1, and other factors, stimulating regeneration from both α- and non-αRGCs (bottom left); Pten deletion combined with Zymosan strongly augments outgrowth from both subtypes (bottom right) [8]. Asterisks show lesion site.CC BY · PubMed Central
Figure 3 CNTF gene therapy induces optic nerve regeneration by augmenting inflammation and chemokine CCL5. (a) Recombinant CNTF protein (1 µg) does not induce appreciable regeneration. (b,c) Unlike a control adeno-associated protein expressing green fluorescent protein (AAV2-GFP), AAV2 expressing CNTF induces appreciable levels. (d,e) Whereas mice heterozygous for the chemokine 2 receptor (CCR2+/−) regenerate axons in response to CNTF gene therapy (d), homozygous null mice show a strongly diminished response (e). (f,g) CRISPR-Cas9 mediated deletion of the chemokine 5 receptor CCR5. Mice received intraocular injection of an adeno-associated virus expressing Cas9 driven by the synuclein-g promoter plus a second virus expressing either GFP ((f), control) or a small guide RNA directed to CCR5 (g), which nearly eliminated regeneration induced by CNTF gene therapy. (h) Recombinant CCL5 induces nearly as much regeneration as CNTF gene therapy. Asterisks indicate lesion site [22].
Figure 3 CNTF gene therapy induces optic nerve regeneration by augmenting inflammation and chemokine CCL5. (a) Recombinant CNTF protein (1 µg) does not induce appreciable regeneration. (b,c) Unlike a control adeno-associated protein expressing green fluorescent protein (AAV2-GFP), AAV2 expressing CNTF induces appreciable levels. (d,e) Whereas mice heterozygous for the chemokine 2 receptor (CCR2+/−) regenerate axons in response to CNTF gene therapy (d), homozygous null mice show a strongly diminished response (e). (f,g) CRISPR-Cas9 mediated deletion of the chemokine 5 receptor CCR5. Mice received intraocular injection of an adeno-associated virus expressing Cas9 driven by the synuclein-g promoter plus a second virus expressing either GFP ((f), control) or a small guide RNA directed to CCR5 (g), which nearly eliminated regeneration induced by CNTF gene therapy. (h) Recombinant CCL5 induces nearly as much regeneration as CNTF gene therapy. Asterisks indicate lesion site [22].CC BY · PubMed Central
Figure 4 Synergy between intraocular inflammation and deleting receptors for cell-extrinsic suppressors of axon growth. (a–f) Longitudinal sections through the optic nerves of wild-type mice (WT) or mice lacking all 3 isoforms of the Nogo receptor (NgR123−/−) or of NgR1 and 3 plus PTPs, a receptor that mediates inhibitory effects of chondroitin sulfate proteoglycans (CSPGs). As indicated, mice either underwent optic nerve injury alone or with intraocular inflammation following intraocular injection of zymosan. (a’–f’) Regions of optic nerves shown at greater magnification in the corresponding panels below. Note the dramatic increase in regeneration when combining intraocular inflammation with deletion of receptors for the inhibitory molecules associated with myelin and CSPGs. Asterisks show lesion site [40].
Figure 4 Synergy between intraocular inflammation and deleting receptors for cell-extrinsic suppressors of axon growth. (a–f) Longitudinal sections through the optic nerves of wild-type mice (WT) or mice lacking all 3 isoforms of the Nogo receptor (NgR123−/−) or of NgR1 and 3 plus PTPs, a receptor that mediates inhibitory effects of chondroitin sulfate proteoglycans (CSPGs). As indicated, mice either underwent optic nerve injury alone or with intraocular inflammation following intraocular injection of zymosan. (a’–f’) Regions of optic nerves shown at greater magnification in the corresponding panels below. Note the dramatic increase in regeneration when combining intraocular inflammation with deletion of receptors for the inhibitory molecules associated with myelin and CSPGs. Asterisks show lesion site [40].CC BY · PubMed Central
Figure 5 Injury-induced pathways contributing to RGC death after optic nerve injury. Encircled question marks (?) indicate as yet unknown relationships. Up arrows indicate increases.
Figure 5 Injury-induced pathways contributing to RGC death after optic nerve injury. Encircled question marks (?) indicate as yet unknown relationships. Up arrows indicate increases.CC BY · PubMed Central
Figure 6 Phagocytic microglia/monocytes alter the local environment of the injury site and modulate axon regeneration. (a) Single confocal planes with orthogonal views of myelin basic protein (MBP) debris inside CR3+ cells. Images are from 0.2 and 0.4 mm distal to the injury site at 14 DPI [44]. (b) CR3+ microglia and monocytes expand within the site of injury (dotted line) from 1 to 5 days after crush, resulting in a progressive clearance of MBP from the distal optic nerve, allowing for uninhibited axon regeneration [44]. (c) Treatment with CSF1R inhibitor, PLX5622 (PLX) results in efficient clearance of IBA1+ microglia from the retina, which is maintained by 14 days after ONI (14d post-ONI). (d) Microglia deletion enhances the number of GAP43+ (green) axons regenerating past the crush site (dotted line). Right: Quantitation of regenerating axons 0.5 mm distal to the injury site (☐); mean ± s.e.m, n = optic nerves, **, p ≤ 0.01 by t-test [44].
Figure 6 Phagocytic microglia/monocytes alter the local environment of the injury site and modulate axon regeneration. (a) Single confocal planes with orthogonal views of myelin basic protein (MBP) debris inside CR3+ cells. Images are from 0.2 and 0.4 mm distal to the injury site at 14 DPI [44]. (b) CR3+ microglia and monocytes expand within the site of injury (dotted line) from 1 to 5 days after crush, resulting in a progressive clearance of MBP from the distal optic nerve, allowing for uninhibited axon regeneration [44]. (c) Treatment with CSF1R inhibitor, PLX5622 (PLX) results in efficient clearance of IBA1+ microglia from the retina, which is maintained by 14 days after ONI (14d post-ONI). (d) Microglia deletion enhances the number of GAP43+ (green) axons regenerating past the crush site (dotted line). Right: Quantitation of regenerating axons 0.5 mm distal to the injury site (☐); mean ± s.e.m, n = optic nerves, **, p ≤ 0.01 by t-test [44].CC BY · PubMed Central
Figure 7 Full-length optic nerve regeneration. (a) Intraocular inflammation combined with CPT-cAMP and virally mediated PTEN deletion enables RGCs to regenerate axons the full length of the optic nerve in 8–10 weeks. Axons are labeled by intraocular injection of cholera toxin B fragment (CTB, red). (b) Control optic nerve in case treated with intraocular Zymosan and a control virus. (c–e) Enlargements of area within rectangle show overlap in immunostaining fibers for CTB (c, red) and the growth-associated protein GAP43 (d, green). Asterisks show lesion site [79].
Figure 7 Full-length optic nerve regeneration. (a) Intraocular inflammation combined with CPT-cAMP and virally mediated PTEN deletion enables RGCs to regenerate axons the full length of the optic nerve in 8–10 weeks. Axons are labeled by intraocular injection of cholera toxin B fragment (CTB, red). (b) Control optic nerve in case treated with intraocular Zymosan and a control virus. (c–e) Enlargements of area within rectangle show overlap in immunostaining fibers for CTB (c, red) and the growth-associated protein GAP43 (d, green). Asterisks show lesion site [79].CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. Xie L. Yin Y. Peterson S.L. Jayakar S. Shi C. Lenfers Turnes B. Zhang Z. Oses-Prieto J. Li J. Burlingame A. The atypical receptor-ligand pair Ocm-R/oncomodulin enables axon regeneration in the central and peripheral nervous systems Proceedings of the Society for Neuroscience San Diego, CA, USA 12–16 November2022
  2. Feng Q. Wong K.A. Peterson S.L. Benowitz L. Harnessing neuroinflammation to promote axon regeneration after optic nerve injury Proceedings of the Association for Research in Vision and Ophthalmology Annual Meeting Vancouver, BC, Canada 28 April–2 May 2019

Cited by

See all 73

Metadata

Authors
Wong, K. A., & Benowitz, L. I.
Affiliations
Boston Children's Hospital (US)
Corresponding author
  • Wong, Kimberly A.
  • Benowitz, Larry I.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-09-05
Volume
23
Issue
17
Pages
10179
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4294733128
Cited by
66
References
99
Citations by year
2026: 14 · 2025: 15 · 2024: 19 · 2023: 18
FWCI
1.85
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Gilbert Family Foundation Vision Restoration Initiative (HD018655)
  • Miriam and Sheldon G. Adelson Medical Research Foundation (HD018655)
  • NIH Intellectual and Developmental Disabilities Research Centers Imaging Core of Boston Children’s Hospital (HD018655)
  • BrightFocus National Glaucoma Research Postdoctoral Award (HD018655)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
Keywords
retinal ganglion cells, optic nerve injury, axon regeneration, retinal ganglion cell survival, inflammation, innate immune system, glaucoma, optic neuropathy, optic pathway glioma, signaling pathways, transcription factors, vision loss
MeSH terms
Axons, Cell Survival, Humans, Inflammation, Nerve Regeneration, Retinal Ganglion Cells, Optic Nerve Injuries

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.